Cartesian Therapeutics, Inc.
RNAC- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001453687
No open-market purchases or sales by Cartesian Therapeutics, Inc. insiders were filed in the last 90 days; 94 institutions reported holding it in 13F filings for Q2 2026, worth $90.4M in total; no superinvestor holds it.
13F holders, Q4 2021
Institutional positions in Cartesian Therapeutics, Inc. as of Dec 31, 2021. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 106
- +4 vs. Q3 2021
- Shares held
- 57.1M
- +7.01M (+14.0%) vs. Q3 2021
- Total value
- $185.7M
- −$23.4M (−11.2%) vs. Q3 2021
- New holders
- 18
- 35 more added
- Sold out
- 14
- 33 more reduced
1 institution that held it in Q3 2021 haven't filed for Q4 2021 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2021: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting RNAC on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 94 | $90.4M |
| Q1 2026 | 83 | $43.9M |
| Q4 2025 | 67 | $37.2M |
| Q3 2025 | 68 | $60.9M |
| Q2 2025 | 66 | $66.5M |
| Q1 2025 | 72 | $86.7M |
| Q4 2024 | 68 | $119.5M |
| Q3 2024 | 64 | $110.3M |
| Q2 2024 | 62 | $88.3M |
| Q1 2024 | 70 | $35.3M |
| Q4 2023 | 80 | $37.8M |
| Q3 2023 | 87 | $57.2M |
| Q2 2023 | 92 | $63.2M |
| Q1 2023 | 95 | $65.1M |
| Q4 2022 | 86 | $62.8M |
| Q3 2022 | 97 | $104.9M |
| Q2 2022 | 93 | $79.3M |
| Q1 2022 | 102 | $71.6M |
| Q4 2021 | 106 | $185.7M |
| Q3 2021 | 103 | $216.7M |
| Q2 2021 | 101 | $219.2M |
| Q1 2021 | 98 | $245.1M |
Institutions, Q4 2021
Shares, value and share of portfolio for each institution holding Cartesian Therapeutics, Inc.; share changes are against Q3 2021.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Endurant Capital Management LP | 2,123,526 | $6.92M | 1.87% | +1,102,025+107.9% | Added |
| Boxer Capital, LLC | 3,284,072 | $10.7M | 0.43% | 00.0% | Unchanged |
| NanoDimension, Inc. | 3,647,907 | $11.9M | 10.66% | +3,647,907 | New |
| Artal Group S.A. | 4,000,000 | $13.0M | 0.38% | 00.0% | Unchanged |
| Vanguard Group Inc | 5,168,231 | $16.8M | 0.00% | +104,234+2.1% | Added |
| BlackRock Inc. | 6,951,882 | $22.7M | 0.00% | −13,714−0.2% | Reduced |
| Acuta Capital Partners, LLC | 0 | $0 | 0.00% | −1,024,668−100.0% | Sold out |
| Bank of Montreal | 0 | $0 | 0.00% | −609,507−100.0% | Sold out |
| Arrowstreet Capital, Limited Partnership | 0 | $0 | 0.00% | −185,839−100.0% | Sold out |
| Alps Advisors Inc | 0 | $0 | 0.00% | −141,050−100.0% | Sold out |
| Opaleye Management Inc. | 0 | $0 | 0.00% | −106,000−100.0% | Sold out |
| Norges Bank | 0 | $0 | 0.00% | −99,400−100.0% | Sold out |
| Capital Fund Management S.A. | 0 | $0 | 0.00% | −63,176−100.0% | Sold out |
| Prudential Financial Inc | 0 | $0 | 0.00% | −41,740−100.0% | Sold out |
| HighVista Strategies LLC | 0 | $0 | 0.00% | −22,269−100.0% | Sold out |
| Beacon Pointe Advisors, LLC | 0 | $0 | 0.00% | −19,000−100.0% | Sold out |
| Parametric Portfolio Associates LLC | 0 | $0 | 0.00% | −18,570−100.0% | Sold out |
| Advisory Services Network, LLC | 0 | $0 | 0.00% | −10,000−100.0% | Sold out |
| Penserra Capital Management LLC | 0 | $0 | 0.00% | −2,630−100.0% | Sold out |
| Ellevest, Inc. | 0 | $0 | 0.00% | −50−100.0% | Sold out |
| Marshall Wace North America L.P. | – | – | – | – | Not filed |